CBIO - タ―ガセプト （Catalyst Biosciences Inc. ） タ―ガセプトCBIOのチャート
CBIOの企業情報
| symbol | CBIO |
|---|---|
| 会社名 | Catalyst Biosciences Inc （タ―ガセプト） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 カタリスト・バイオサイエンシズ（Catalyst Biosciences Inc.）(旧名：Targacept Inc.)は臨床段階のバイオ医薬品会社である。同社は、重篤な疾患に対処する医薬品の作成・開発に焦点を当てる。同社は、血友病及び外科出血の治療を含む止血、及び腎臓移植における移植後腎機能発現遅延の予防及び視覚障害や失明を引き起こす可能性がある萎縮型加齢黄斑変性症の治療を含む炎症等の分野を中心として製品開発に取り組む。同社の止血製品候補は、CB 813d/PF-0520602、CB 2679d/ISU 304とFXaを含む。同社の炎症開発候補は、CB2782及び眼科を含む。同社の技術は、移植後腎機能発現遅延（DGF）のためのCB 2782、及び萎縮型加齢黄斑変性症（萎縮型AMD）プログラムにおけるリードを含む抗C3プロテアーゼを選択する。 タ―ガセプトは米国の神経系疾患と消化器疾患の治療薬に焦点を置くバイオ医薬品会社。ニコチン性ニュ―ロン受容体をタ―ゲットにした治療薬「NNRセラピュ―ティクス」の開発を行い、糖尿病性胃不全麻痺、統合失調症、アルツハイマ―病、注意欠陥多動性障害の治療薬として治験を行う。 |
| 本社所在地 | 260 Littlefield Ave. South San Francisco NC 94080 USA |
| 代表者氏名 | Augustine J. Lawlor アウグスティヌス・J・ローラー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-745-0655 |
| 設立年月日 | 35490 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 19人 |
| url | www.catalystbiosciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.34800 |
| 終値（lastsale） | 10.24 |
| 時価総額（marketcap） | 122293544.96 |
| 時価総額 | 時価総額（百万ドル） 113.33650 |
| 売上高 | 売上高（百万ドル） 0.64200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -22.80950 |
| 当期純利益 | 当期純利益（百万ドル） -23.07000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Biosciences Inc revenues decreased 98% to $6K. Net loss applicable to common stockholders decreased 17% to $11.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$7.10 to -$1.10. |
CBIOのテクニカル分析
CBIOのニュース
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update 2020/11/05 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial…
Global Hemophilia A Drug Market 2020 to 2028 with top key players like Bayer AG, BioMarin Pharmaceutical, Bioverativ, Catalyst Biosciences 2020/10/08 12:13:06 OpenPR
The new statistical report has recently published by Reports Consultant to its massive repository titled Global Hemophilia A Drug market 2020. This informative document takes a closer and analytical look at different aspects of the businesses to understand the business
Catalyst Biosciences Added to Russell 2000 Index 2020/06/29 12:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the…
Catalyst Biosciences : WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy | MarketScreener 2020/06/19 15:52:19 MarketScreener
Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy World Federation of Hemophilia … | June 19, 2020
Catalyst Biosciences : WFH - Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacogalfa in Hemophilia B | MarketScreener 2020/06/18 21:02:04 MarketScreener
Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B Johnny… | June 18, 2020
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update 2020/11/05 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial…
Global Hemophilia A Drug Market 2020 to 2028 with top key players like Bayer AG, BioMarin Pharmaceutical, Bioverativ, Catalyst Biosciences 2020/10/08 12:13:06 OpenPR
The new statistical report has recently published by Reports Consultant to its massive repository titled Global Hemophilia A Drug market 2020. This informative document takes a closer and analytical look at different aspects of the businesses to understand the business
Catalyst Biosciences Added to Russell 2000 Index 2020/06/29 12:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the…
Catalyst Biosciences : WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy | MarketScreener 2020/06/19 15:52:19 MarketScreener
Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy World Federation of Hemophilia … | June 19, 2020
Catalyst Biosciences : WFH - Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacogalfa in Hemophilia B | MarketScreener 2020/06/18 21:02:04 MarketScreener
Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B Johnny… | June 18, 2020
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update 2020/11/05 13:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial…
Global Hemophilia A Drug Market 2020 to 2028 with top key players like Bayer AG, BioMarin Pharmaceutical, Bioverativ, Catalyst Biosciences 2020/10/08 12:13:06 OpenPR
The new statistical report has recently published by Reports Consultant to its massive repository titled Global Hemophilia A Drug market 2020. This informative document takes a closer and analytical look at different aspects of the businesses to understand the business
Catalyst Biosciences Added to Russell 2000 Index 2020/06/29 12:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the…
Catalyst Biosciences : WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy | MarketScreener 2020/06/19 15:52:19 MarketScreener
Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy World Federation of Hemophilia … | June 19, 2020
Catalyst Biosciences : WFH - Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacogalfa in Hemophilia B | MarketScreener 2020/06/18 21:02:04 MarketScreener
Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog alfa in Hemophilia B Johnny… | June 18, 2020